龟鹿二仙胶通过调控PD-1表达抑制H22荷瘤小鼠肿瘤生长的研究(1)
[摘要] 目的 初步探讨龟鹿二仙胶通过降低肿瘤周围T淋巴细胞PD-1表达，抑制T细胞凋亡，从而抑制肿瘤生长的分子机制。 方法 采用皮下接种H22肝癌细胞株方法建立荷瘤小鼠模型，观察藥物干预后各组荷瘤小鼠肿瘤的生长速度，Annexin V/PI双染色法测定小鼠脾脏T淋巴细胞凋亡比例，分离肿瘤浸润性T淋巴细胞，流式细胞检测PD-1阳性细胞的比例。 结果 (1)龟鹿二仙胶呈剂量依赖抑制皮下瘤的生长，顺铂组及高、中、低剂量组抑瘤率分别为81.36%、79.64%、48.86%、21.96%;(2)顺铂组及高、中、低剂量组小鼠T淋巴细胞凋亡比例分别为早期(24.37±0.32)%、(5.30±0.21)%、(6.90±0.16)%、(11.93±2.01)%;晚期(8.83±1.23)%、(4.73±0.33)%、(6.40±0.34)%、(7.47±0.54)%，说明与顺铂组比较，龟鹿二仙胶能够抑制小鼠T淋巴细胞凋亡;(3)龟鹿二仙胶高剂量组、中剂量组的PD-1表达阳性细胞比分别为(11.73±0.54)%、(20.00±0.66)%，明显低于生理盐水组(32.57±0.65)%和顺铂组(31.83±0.43)%，说明龟鹿二仙胶能够降低肿瘤浸润T淋巴细胞中PD-1阳性的比例。 结论 龟鹿二仙胶具有抑制肿瘤生长的作用，其机制可能是通过抑制PD-1表达，减少T淋巴细胞凋亡，增强机体免疫力，从而抑制和杀伤肿瘤细胞得以实现的。
[关键词] 龟鹿二仙胶;T淋巴细胞;PD-1;凋亡
[中图分类号] R285.5 [文献标识码] A [文章编号] 1673-9701(2018)36-0001-05
[Abstract] Objective To investigate the molecular mechanism of Guilu Erxianjiao in inhibiting tumor growth and inhibiting T cell apoptosis by reducing the expression of PD-1 in T lymphocytes around the tumor. Methods The tumor-bearing mouse model was established by subcutaneous inoculation of H22 hepatoma cell line. The growth rate of tumor-bearing mice in each group was observed after drug intervention. Annexin V/PI double staining was used to detect the percentage of apoptosis of mouse spleen T lymphocytes. Tumor infiltrating T lymphocytes were isolated. The proportion of PD-1 positive cells was detected by flow cytometry. Results (1)Guilu Erxianjiao inhibited the growth of subcutaneous tumors in a dose-dependent manner. The tumor inhibition rate of cisplatin group and high， medium and low dose groups was 81.36%， 79.64%， 48.86% and 21.96%， respectively. (2)The percentages of T lymphocyte apoptosis in the cisplatin group， high， medium and low dose groups were early (24.37±0.32)%， (5.30±0.21)%， (6.90±0.16)%， (11.93±2.01)%， and late (8.83±1.23)%， (4.73±0.33)%， (6.40±0.34)%， (7.47±0.54)%， indicating that compared with cisplatin group， Guilu Erxianjiao could inhibit the apoptosis of mouse T lymphocytes. (3)The ratio of PD-1 positive cells in Guilu Erxianjiao high dose group and medium dose group of was(11.73±0.54)% and (20.00±0.66)%， which was significantly lower than that in the saline group (32.57±0.65)% and cisplatin group (31.83±0.43)%， indicating that Guilu Erxianjiao could reduce the proportion of PD-1 positive in tumor infiltrating T lymphocytes. Conclusion Guilu Erxianjiao has the effect of inhibiting tumor growth. This may be achieved by inhibiting PD-1 expression， reducing T lymphocyte apoptosis， enhancing immunity to inhibit and kill tumor cell., 百拇医药(钟亚珍 林贤雷 陆金华 林胜友)
[关键词] 龟鹿二仙胶;T淋巴细胞;PD-1;凋亡
[中图分类号] R285.5 [文献标识码] A [文章编号] 1673-9701(2018)36-0001-05
[Abstract] Objective To investigate the molecular mechanism of Guilu Erxianjiao in inhibiting tumor growth and inhibiting T cell apoptosis by reducing the expression of PD-1 in T lymphocytes around the tumor. Methods The tumor-bearing mouse model was established by subcutaneous inoculation of H22 hepatoma cell line. The growth rate of tumor-bearing mice in each group was observed after drug intervention. Annexin V/PI double staining was used to detect the percentage of apoptosis of mouse spleen T lymphocytes. Tumor infiltrating T lymphocytes were isolated. The proportion of PD-1 positive cells was detected by flow cytometry. Results (1)Guilu Erxianjiao inhibited the growth of subcutaneous tumors in a dose-dependent manner. The tumor inhibition rate of cisplatin group and high， medium and low dose groups was 81.36%， 79.64%， 48.86% and 21.96%， respectively. (2)The percentages of T lymphocyte apoptosis in the cisplatin group， high， medium and low dose groups were early (24.37±0.32)%， (5.30±0.21)%， (6.90±0.16)%， (11.93±2.01)%， and late (8.83±1.23)%， (4.73±0.33)%， (6.40±0.34)%， (7.47±0.54)%， indicating that compared with cisplatin group， Guilu Erxianjiao could inhibit the apoptosis of mouse T lymphocytes. (3)The ratio of PD-1 positive cells in Guilu Erxianjiao high dose group and medium dose group of was(11.73±0.54)% and (20.00±0.66)%， which was significantly lower than that in the saline group (32.57±0.65)% and cisplatin group (31.83±0.43)%， indicating that Guilu Erxianjiao could reduce the proportion of PD-1 positive in tumor infiltrating T lymphocytes. Conclusion Guilu Erxianjiao has the effect of inhibiting tumor growth. This may be achieved by inhibiting PD-1 expression， reducing T lymphocyte apoptosis， enhancing immunity to inhibit and kill tumor cell., 百拇医药(钟亚珍 林贤雷 陆金华 林胜友)